Investigation
BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Menu
Investigation
08/01/2022
Initial Lawsuit
08/31/2022
Lawsuit Progression
To be active
A TuSimple Holdings Inc. (TSP) investor filed a federal securities class action on behalf of all persons who:
(a) purchased or otherwise acquired TuSimple common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with TuSimple’s April 15, 2021, initial public offering (IPO); and/or
(b) that purchased or otherwise acquired TuSimple securities between April 15, 2021, and August 1, 2022, both dates inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) TuSimple’s commitment to safety was significantly overstated and the defendants concealed fundamental problems with the company’s technology;
(ii) TuSimple was rushing the testing of its autonomous driving technology in order to deliver driverless trucks to the market ahead of its more safety-conscious competitors;
(iii) there was a corporate culture within TuSimple that suppressed or ignored safety concerns in favor of unrealistically ambitious testing and delivery schedules;
(iv) the aforementioned conduct made accidents involving the company’s autonomous driving technology more likely;
(v) the aforementioned conduct invited enhanced regulatory scrutiny and investigatory action toward the company; and
(iv) as a result, the company’s public statements were materially false and misleading at all relevant times.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.